SCHEDULE: Bain Capital Backs Mersana Therapeutics Tender Offer

Bain Capital Life Sciences entities have agreed to tender their 6.9% stake in Mersana Therapeutics as part of a tender offer by Day One Biopharmaceuticals.

Summary

• Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, and BCLS II Investco, LP (collectively, the "Reporting Persons") filed an Amendment No. 7 to their Schedule 13D.
• The amendment discloses that Mersana Therapeutics, Inc. entered into a Merger Agreement with Day One Biopharmaceuticals, Inc. and its subsidiary, Emerald Merger Sub, Inc., on November 12, 2025.
• Under this agreement, Emerald Merger Sub, Inc. will launch a tender offer to acquire all outstanding shares of Mersana Therapeutics.
• In connection with the merger agreement, the Reporting Persons signed a Tender and Support Agreement on November 12, 2025.
• This Support Agreement commits the Reporting Persons to tender their shares in the offer and, if applicable, vote in favor of the merger.
• The Reporting Persons collectively beneficially own 346,545 shares of Mersana Therapeutics Common Stock, representing approximately 6.9% of the outstanding shares.
• This percentage is based on 4,990,692 shares outstanding as of August 8, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a significant step towards a corporate acquisition, providing a clear exit for the reporting persons' investment. While the specific financial terms of the tender offer are not disclosed here, the commitment to tender shares suggests a positive or at least acceptable outcome for the reporting shareholders. The transaction is a definitive event, reducing uncertainty for these specific investors.

Positives

• The Reporting Persons have secured an agreement to tender their shares, indicating a clear exit strategy for their investment in Mersana Therapeutics.
• The tender offer provides liquidity for the Reporting Persons' significant stake.

Negatives

• The agreement includes restrictions on the Reporting Persons' ability to take actions with respect to Mersana Therapeutics and its Common Stock, limiting their flexibility until the transaction concludes or terminates.

Risks

• The tender offer is subject to certain exceptions and the valid termination of the Merger Agreement, meaning the transaction is not yet finalized and could still fall through.
• The value of the tender offer is not disclosed in this filing, so the financial outcome for the Reporting Persons is not explicitly stated as positive or negative in terms of return.

Future Outlook

The filing indicates a clear path towards the acquisition of Mersana Therapeutics by Day One Biopharmaceuticals through a tender offer, with a significant shareholder group committing to support the transaction.

Industry Context

This transaction reflects ongoing consolidation and strategic M&A activity within the biotechnology sector, where larger pharmaceutical companies or well-funded biotechs acquire smaller, innovative firms to expand their pipelines or technology platforms. Bain Capital's support signals confidence in the acquisition terms.

Comparison to Industry Standards

• The commitment of a major institutional investor like Bain Capital to tender its shares in a merger or acquisition is a standard practice when such a transaction is announced, especially when the terms are deemed favorable or acceptable.
• The percentage of shares committed (6.9%) is a significant block, providing substantial support for the tender offer's success, comparable to other M&A deals where key institutional holders pre-commit.
• The structure of a tender offer followed by a merger is a common mechanism for acquisitions in the U.S. market, particularly for public companies.

Stakeholder Impact

• Shareholders: The tender offer provides an opportunity for all shareholders of Mersana Therapeutics to sell their shares, likely at a premium, offering liquidity and a definitive exit.
• Employees: The merger could lead to changes in management, operations, or workforce at Mersana Therapeutics, depending on Day One Biopharmaceuticals' integration plans.
• Customers/Suppliers: The impact on customers and suppliers is generally indirect, potentially involving changes in product strategy or supply chain management post-acquisition.

Next Steps

• Emerald Merger Sub, Inc. will commence a tender offer to acquire all issued and outstanding shares of Mersana Therapeutics, Inc.
• Reporting Persons will tender their shares in the Offer, subject to certain exceptions.
• If applicable, Reporting Persons will vote their shares in favor of the Merger.

Key Dates

Recommendation

This filing indicates that a significant institutional investor, Bain Capital, has committed to tendering its shares in an upcoming acquisition of Mersana Therapeutics. For existing shareholders, the tender offer typically represents a defined exit at a specific price. While the price itself is not disclosed in this filing, the commitment from a major investor suggests the terms are likely acceptable. Therefore, for current shareholders, holding until the tender offer commences and evaluating its terms would be the prudent action. For potential new investors, entering the stock at this stage carries the risk of limited upside if the tender offer price is already factored into the market, and the primary opportunity is for existing holders to realize value.

Keywords

Mersana Therapeutics, Day One Biopharmaceuticals, Bain Capital Life Sciences, Tender Offer, Merger Agreement, Schedule 13D, Support Agreement, Biotechnology, Acquisition, Shareholder Agreement